国际肝病采访APASL2009大会主席廖家杰教授

帅庭

文章导读：In the ordinary circumstances, we mainly pay attention to the HBV DNA level during the treatment of hepatitis B. But HBV DNA is not the target of the immune response; the immune response is antigen-antibody reaction, such as HBeAg, HBsAg and so on.George K.K. Lau  Department of Medicine, The University of Hong Kong，Hong Kong SAR，China

Hepatology Digest: According to your study about PEG-IFN a-2a for HBeAg-positive chronic hepatitis B, we know that quantitative HBeAg is a useful adjunctive measurement for predicting HBeAg seroconversion in patients treated with PEG-IFN when considering both sensitivity and specificity compared with serum HBV DNA. So what’s your view on the future of quantitative HBeAg for predicting HBeAg seroconversion?

Pro. Lau: In the ordinary circumstances, we mainly pay attention to the HBV DNA level during the treatment of hepatitis B. But HBV DNA is not the target of the immune response; the immune response is antigen-antibody reaction, such as HBeAg, HBsAg and so on. Therefore, the negative conversion for HBeAg and HBsAg during treatment also needs to strive for. However, up to now we do not pay much attention to the decline in the HBeAg or HBsAg speed, we have just only paid much attention to observing the level of HBV DNA. We also know that the therapeutic response of HBV DNA and HBeAg, HBsAg is different. We can only carry out HBeAg and HBsAg qualitative detection before while now we can carry out HBeAg and HBsAg quantitative detection. During the process of antigen negative conversion,
更多精彩内容请点击：http://apasl2009-cn.ihepa.com/17-171-2066.html]

走遍四方

去看了下，没看到好东西。

ybdn

原帖由 hcs_usst 于 2009-2-16 15:39 发表
去看了下，没看到好东西。

应该是说好东西还是不少的,只是没有革命性的让人振奋的消息。